**ADDITIONAL FILE 2: Comments from Member Open Review**

Comments from the member open review of this consensus statement will be published with this document.

|  |  |
| --- | --- |
| **Comment Date** | **Comments** |
| **4/18/2018** | Correction starting at line 308. Most recently, a phase III trial comparing first line pembrolizumab plus chemotherapy (pemetrexed plus cisplatin or carboplatin) versus chemotherapy alone in 616 patients with advanced or metastatic NSCLC, irrespective of PD-L1 expression, met its co-primary endpoints of improved OS and PFS. |
| **4/18/2018** | * Line 79, 216, 355-356: Suggest adding the word "unresectable stage III" to describe durvalumab indication
* Line 235: Nivolumab is listed as a "fully humanized" mAb, whereas it is actually a fully human mAb. Pembrolizumab is correctly stated as "fully humanized" (line 255)
* Line 244-245: The way this is written suggests that nivolumab was approved at the 240 mg flat dose.
* Line 247: Suggest adding that long-term 3-year data from these studies demonstrate durable responses and OS (Annals of Oncology)
* Line 248-250: The 541 patients included in CM026 were at >1% PD-L1 expression but line 250 suggests they were at >5%, which was the primary endpoint population. Only 423 patients had >5% PD-L1 expression.
* Line 271-272: The way this is written suggests that pembrolizumab was approved at the 200 mg flat dose.
* Line 287-288: Should specify the KN021G was in nonsquamous only.
* Line 383: It states "no evidence to use one drug over the other" but this does omit the fact that pembrolizumab is not approved for 2L PD-L1 non-expressors.
* Line 384 (and throughout): Can mention of the nivolumab 480 mg Q4W dose and schedule be added wherever relevant?
 |